Want to see AU:CUV full AI Analyst Report?
Top Page
Clinuvel Pharmaceuticals
(Sydney:CUV)
Select Model
Select Model
Rating:72Outperform
Price Target:
AU$11.50
▲(3.79% Upside)
Action:Reiterated
Date:04/03/26
Score is driven primarily by strong financial performance (profitability, cash generation, and a debt-free balance sheet). This is tempered by weak technical momentum with the stock trading below key moving averages and a negative MACD. Valuation appears reasonable, while the earnings call was constructive on cash strength and catalysts but flagged meaningful expense increases and timing/regulatory risks.
Positive Factors
Strong, Debt-free Balance Sheet
Clinuvel's large cash balance and 21-year debt-free record create durable financial flexibility. With term deposits earning ~4.5% and positive operating cash flow, the company can fund clinical programs, manufacturing scale-up and commercialization without reliance on dilution or external debt, reducing financing risk over the medium term.
Negative Factors
Rising Operating Costs
A meaningful step-up in operating spend—across personnel, commercial distribution and R&D consumables—raises the company's fixed cost base. If revenue growth does not accelerate to match these investments, margin compression and longer payback on R&D and commercialization investments could pressure cash conversion and strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong, Debt-free Balance Sheet
Clinuvel's large cash balance and 21-year debt-free record create durable financial flexibility. With term deposits earning ~4.5% and positive operating cash flow, the company can fund clinical programs, manufacturing scale-up and commercialization without reliance on dilution or external debt, reducing financing risk over the medium term.
Read all positive factors
Clinuvel Pharmaceuticals (CUV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$525.46M
Dividend Yield0.38%
Average Volume (3M)97.23K
Price to Earnings (P/E)16.0
Beta (1Y)0.69
Revenue Growth5.17%
EPS Growth-16.14%
CountryAU
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.65
Shares Outstanding50,427,900
10 Day Avg. Volume118,433
30 Day Avg. Volume97,231
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.16
Price to Sales (P/S)5.47
P/FCF Ratio12.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$28.10Price Target Upside153.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.77
Revenue Forecast (FY)AU$105.43M
Clinuvel Pharmaceuticals Business Overview & Revenue Model
Company Description
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, t...
How the Company Makes Money
Clinuvel makes money primarily from sales of its lead product, SCENESSE (afamelanotide), in markets where it has received regulatory approval. Revenue is generated by supplying SCENESSE to healthcare systems and treatment centers for use in eligib...
Clinuvel Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 25, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Sep 01, 2026
Earnings Call Sentiment Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.Positive Updates
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Negative Updates
Overall Expense Growth
Total expenses increased 22% for the period, driven by the company’s expansion initiatives and higher operating activity, resulting in lower net profit relative to prior periods.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Record First-Half Sales
Sales revenue increased 4% year-on-year to just under $37 million, marking the company's highest-ever first-half sales and continuing a steady growth pattern.
Read all positive updates
Company Guidance
Guidance from the call was that CLINUVEL will continue a controlled expansion while tightly managing costs, with full‑year operating expense guidance of about A$55–58m (ex‑capex); H1 sales rose 4% YoY to just under A$37m (the highest H1 on record), interest income was A$5.3m (up 14%), cash increased by A$9m to A$233m, net assets rose A$8.2m to ~A$250m, the company remains debt‑free for a 21st year and has delivered its 20th consecutive profit. Management flagged expense drivers (total expenses +22%: personnel +16%, commercial distribution +42%, finance/legal +47%, other R&D +191%), lower non‑cash and share‑based charges (share plan now 1‑year), term deposits average ~300 days at ~4.5% yield, revenue split ~53% U.S./47% RoW, <5% U.S. patients on Medicaid, and near‑term catalysts include CUV105 topline in H2 2026, start of CUV107, peptide preclinical data H2 2026 and the ADR/NASDAQ uplift pending SEC responses.Clinuvel Pharmaceuticals Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
90
Very Positive
Cash Flow
80
Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 96.30M | 95.02M | 88.18M | 78.32M | 65.72M | 47.98M |
| Gross Profit | 61.36M | 79.14M | 80.45M | 50.59M | 46.62M | 35.20M |
| EBITDA | 41.65M | 57.20M | 56.28M | 46.37M | 35.08M | 28.19M |
| Net Income | 32.54M | 36.17M | 35.64M | 30.60M | 20.88M | 24.73M |
Balance Sheet | ||||||
| Total Assets | 269.70M | 271.75M | 231.12M | 194.52M | 144.81M | 108.57M |
| Cash, Cash Equivalents and Short-Term Investments | 233.00M | 224.11M | 183.87M | 156.81M | 121.51M | 82.69M |
| Total Debt | 341.09K | 528.53K | 879.78K | 999.87K | 1.26M | 1.30M |
| Total Liabilities | 20.68M | 30.94M | 28.11M | 29.89M | 19.25M | 9.83M |
| Stockholders Equity | 249.02M | 240.81M | 203.01M | 164.63M | 125.56M | 98.74M |
Cash Flow | ||||||
| Free Cash Flow | 40.08M | 40.80M | 31.48M | 35.88M | 39.44M | 18.41M |
| Operating Cash Flow | 40.47M | 41.10M | 37.05M | 36.91M | 39.87M | 19.26M |
| Investing Cash Flow | -18.64M | -47.72M | -29.03M | -1.03M | -434.44K | -854.33K |
| Financing Cash Flow | -2.71M | -2.94M | -3.57M | -2.24M | -1.50M | -1.48M |
Clinuvel Pharmaceuticals Technical Analysis
Positive
11.08
Price Trends
9.35
Positive
9.72
Positive
10.79
Negative
Market Momentum
0.31
Negative
65.55
Neutral
74.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CUV, the sentiment is Positive. The current price of 11.08 is above the 20-day moving average (MA) of 9.61, above the 50-day MA of 9.35, and above the 200-day MA of 10.79, indicating a neutral trend. The MACD of 0.31 indicates Negative momentum. The RSI at 65.55 is Neutral, neither overbought nor oversold. The STOCH value of 74.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CUV.
Clinuvel Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$525.46M | 16.02 | 13.29% | 0.38% | 5.17% | -16.14% | |
53 Neutral | AU$70.68M | 72.09 | 17.85% | ― | 38.44% | 230.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$1.65B | -19.31 | -30.03% | ― | ― | 22.52% | |
47 Neutral | AU$298.86M | -94.81 | -15.96% | ― | 364.97% | 74.50% | |
46 Neutral | AU$6.80M | -2.24 | -211.88% | ― | 250.37% | 71.29% | |
45 Neutral | AU$60.15M | -0.47 | -131.13% | ― | 2086.71% | -116.20% |
* Healthcare Sector Average
AU:CUV
Clinuvel Pharmaceuticals
10.42
0.48
4.82%
AU:ACR
Acrux
0.01
>-0.01
-27.78%
AU:SPL
Starpharma Holdings Limited
0.71
0.62
716.09%
AU:PYC
PYC Therapeutics Limited
1.68
0.41
32.39%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.28
-92.67%
AU:BIO
Biome Australia Ltd
0.31
-0.20
-39.22%
Clinuvel Pharmaceuticals Corporate Events
Clinuvel Files 20-F as It Pursues Nasdaq ADS Uplisting
Jun 16, 2026
Clinuvel Pharmaceuticals has publicly filed a Form 20-F registration statement with the U.S. Securities and Exchange Commission as it seeks to upgrade its existing over-the-counter American Depositary Receipt program to a Level II American Deposit...
Clinuvel Issues 887,956 Unquoted Performance Rights Under Incentive Scheme
May 7, 2026
Clinuvel Pharmaceuticals has notified the market of the issue of 887,956 unquoted performance rights under its employee incentive scheme, with an effective issue date of 30 April 2026. The move signals the company’s continued use of equity-b...
Clinuvel advances Nasdaq Level II ADR plans amid ongoing SEC review
Apr 27, 2026
Clinuvel Pharmaceuticals is a Melbourne‑based specialty drug developer focused on photomedicine and melanocortin‑based therapies for rare genetic and metabolic disorders, led by its flagship photoprotective treatment SCENESSE, which is...
FDA Drops QT Study Requirement for Clinuvel’s SCENESSE
Apr 26, 2026
Clinuvel Pharmaceuticals said the U.S. Food and Drug Administration has removed a requirement for a post‑authorisation cardiac repolarisation, or QT, study for its flagship drug SCENESSE after reviewing extensive long‑term safety data....
Clinuvel Secures EMA Guidance for Pivotal Vitiligo Trial of SCENESSE
Apr 23, 2026
Clinuvel Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design and evaluation framework for its pivotal Phase III CUV107 trial of SCENESSE as a systemic treatment for non-segmental vitiligo. The guid...
Clinuvel Performance Rights Lapse After Conditions Not Met
Apr 16, 2026
Clinuvel Pharmaceuticals has announced the cessation of 46,067 performance rights, which lapsed after the applicable conditions for conversion into securities were not met or became incapable of being satisfied. The move slightly reduces the compa...
Clinuvel Issues New Shares, Confirms Compliance With Disclosure Rules
Apr 12, 2026
Clinuvel Pharmaceuticals has issued 227,158 fully paid ordinary shares at no issue price per share on 2 April 2026, confirming the shares were issued without a prospectus under Australian Corporations Act provisions. The company stated it remains ...
Clinuvel Leverages AAD 2026 to Advance Vitiligo, EPP Strategy and U.S. Profile
Apr 2, 2026
Clinuvel used the 2026 American Academy of Dermatology Annual Meeting in Denver to highlight progress in its vitiligo and erythropoietic protoporphyria (EPP) programs, centering on its melanocortin drug afamelanotide. Case studies from the CUV105 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.